{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-026572","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2022-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.852212+00:00","generated_at":"2026-06-23T03:00:38.210698+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Denali Therapeutics announces $250M public offering of common stock","bullets":["Denali to sell $250M of common stock; underwriters have 30-day option for additional 15%.","Goldman Sachs, J.P. Morgan, and Jefferies act as joint book-running managers for the offering.","Preliminary cash, cash equivalents, and marketable securities estimated at $1.11B as of Sep 30, 2022.","Company has no approved products and expects to continue incurring significant net losses."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-026572","json":"https://secwatch.observer/filing/0001628280-22-026572.json","markdown":"https://secwatch.observer/filing/0001628280-22-026572.md","text":"https://secwatch.observer/filing/0001628280-22-026572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000162828022026572/0001628280-22-026572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000162828022026572/dnli-20221018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:00:38.210698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}